EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Efficacy and safety of the neoadjuvant chemoimmunotherapy with pembrolizumab plus docetaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck

Jing Wang, Wenqian Zhang, Dongning Huang, Zhu Liu, Wei Zhang, Zhendong Li

Frontiers in Immunology · 2025

DOI: 10.3389/fimmu.2025.1664892 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Frontiers in Immunology, 2025. Verfasst von Jing Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Cancer Hospital of China Medical University/Liaoning Cancer Hospital and Institute, Shenyang, China. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Head and Neck Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Head and neck squamous cell carcinoma (HNSCC) is the most common type of tumor originating from the squamous epithelium of the oral cavity, oropharynx, larynx and hypopharynx. There is an urgent need to enhance therapeutic efficacy and ensure the function preservation of HNSCC treatment. This study aimed to evaluate the efficacy and safety of neoadjuvant chemoimmunotherapy with pembrolizumab plus docetaxel and cisplatin in patients with resectable locally advanced HNSCC.

Methods

This was a prospective single-center, single-arm, open-label, phase II study involving patients with locally advanced HNSCC who were treated with pembrolizumab (200 mg) plus docetaxel (50 mg/m 2 ) and cisplatin (50 mg/m 2 ). After two cycles of the neoadjuvant chemoimmunotherapy, patients either proceeded to surgery or refused surgery and continued with chemoimmunotherapy and/or chemoradiotherapy. The primary endpoint was the objective response rate (ORR), while the second endpoints were primary lesion complete pathologic response (pCR), progression-free survival (PFS) rate, overall survival (OS) rate and safety.

Results

Overall, 52 patients with HNSCC were enrolled (45 males/7 females), with a median age of 61 years. The ORR rate was 87.8% (95% confidence interval [CI]: 75.2–95.4). Of the 27 patients who underwent resection, 12 (44.4%, 95% CI: 25.5–64.7) achieved a pCR and 15 (55.6%, 95% CI: 35.3–74.5) achieved an MPR. For the overall population, the PFS rates were 89.8% (95% CI: 77.2–95.6), 87.5% (95% CI: 74.2–94.2), and 72.7% (95% CI: 50.6–86.1), and the OS rates were 95.9% (95% CI: 84.7–99.0), 93.6% (95% CI: 81.5–97.9) and 84.9% (65.0–93.9), at 6 months, 12-months and 18 months, respectively. The most common adverse events were nausea/vomiting (12.2%), fatigue (10.2%), rash (8.2%), neurotoxicity (8.2%) and aminotransferases elevation (8.2%). Grades 3 and 4 adverse events occurred in 12 (24.5%) and 2 (4.1%) patients, respectively.

Conclusions

Pembrolizumab plus docetaxel and cisplatin reveals encouraging survival benefit with a manageable safety profile in patients with HNSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Squamous Cell Carcinoma of Head and NeckAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHead and Neck NeoplasmsHumansMaleFemaleMiddle AgedDocetaxelCisplatinNeoadjuvant TherapyAgedAdultProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

chemotherapycombined positive scorehead and neck cancerimmunotherapyneoadjuvant

Substanzen

DocetaxelAntibodies, Monoclonal, HumanizedCisplatinpembrolizumab

Autor:innen und Institutionen

  • Department of Head and Neck Surgery, Cancer Hospital of China Medical University/Liaoning Cancer Hospital and Institute, Shenyang, China.
  • Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China.

Zitieren

APA

Wang, J., Zhang, W., Huang, D., Liu, Z., Zhang, W., & Li, Z. (2025). Efficacy and safety of the neoadjuvant chemoimmunotherapy with pembrolizumab plus docetaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1664892

Vancouver

Wang J, Zhang W, Huang D, Liu Z, Zhang W, Li Z. Efficacy and safety of the neoadjuvant chemoimmunotherapy with pembrolizumab plus docetaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1664892

BibTeX
@article{Wang2025,
  author = {Wang, Jing and Zhang, Wenqian and Huang, Dongning and Liu, Zhu and Zhang, Wei and Li, Zhendong},
  title = {Efficacy and safety of the neoadjuvant chemoimmunotherapy with pembrolizumab plus docetaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck},
  journal = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1664892}
}
Kostenlos starten →